The risk / benefit balance is “high” in favor of the estrogen vaccine

The World Health Organization (WHO) said on Tuesday that the risk / benefit balance burden continues to be high in favor of the use of the anti-coagulant vaccine AstraZeneca.

Also read: 1,168 new cases in Quebec

Also read: Live | Recent developments on coronavirus

Also read: Vaccine: “We must open the flood gates!”

WHO Regulation in-charge Rogerio Pinto de Sa Gaspar, who described European Medicines Agency (EMA) experts meeting this week to discuss the link between the vaccine and some rare types of thrombosis, said the current state of knowledge, risk / benefit balance is “very positive”.

“These benefits are significant in reducing mortality in the vaccinated population,” he told a WHO press conference dedicated to World Health Day, adding that both experts and the media focused only on the risks.

“The balance (our message) must be restored with the benefits of the vaccine,” he insisted.

Earlier today, an EMA official spoke in an interview with the Italian daily Il Messejero about the existence of a “link” between the astrogenica vaccine and the thrombosis cases observed after its administration.

In the process, the EU agency published an update.

The EMA Security Committee “has not yet reached a decision and is currently under review,” the Amsterdam-based agency told AFP in a statement.

“We will communicate and maintain a press point as soon as the test is finalized,” the European regulator added, noting that there was a statement for Wednesday or Thursday at the end of the committee meeting citing Dr. Pinto. By Saw Gasper.

For several weeks, suspicions of severe side effects appeared, but very rarely, after observation in people vaccinated with estrogenica of atypical thrombosis cases.

Dozens of cases have been identified, most of which have resulted in deaths. In the UK, as of March 24, there were 30 cases and seven deaths out of a total of 18.1 million doses.

As a precaution, many countries, such as France, Germany and Canada, have decided not to vaccinate younger than the specified age group. Norway and Denmark have now completely stopped using it.

For its part, AstraZeneca assured in March that “there was no evidence of an aggravated accident” and on Saturday assured that “patient safety” was its “top priority”.